Matches in Nanopublications for { ?s ?p "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP234867.RA8aBVOXC6BPl67KDBukrmLId7AmSosKie1M8GfCyZ8R0130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP234867.RA8aBVOXC6BPl67KDBukrmLId7AmSosKie1M8GfCyZ8R0130_provenance.
- NP877715.RAwntl_KXR8x90_fvGcCzJHFnL7wViuQrHXapFpLyfhg4130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP877715.RAwntl_KXR8x90_fvGcCzJHFnL7wViuQrHXapFpLyfhg4130_provenance.
- NP493292.RA_8iYW-cjOJu2Z_dMDQUORJN-oXdiSSfpdBaO_V7Edag130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493292.RA_8iYW-cjOJu2Z_dMDQUORJN-oXdiSSfpdBaO_V7Edag130_provenance.
- NP493300.RAxJdgCkqwc7hn-rbTkmfLX2oS12jmRvBNRp0-v232taY130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493300.RAxJdgCkqwc7hn-rbTkmfLX2oS12jmRvBNRp0-v232taY130_provenance.
- NP1404172.RA-HUdBBTVEwcX2BDrEEAolzobTztzmI88UrKHZMnDLPs130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404172.RA-HUdBBTVEwcX2BDrEEAolzobTztzmI88UrKHZMnDLPs130_provenance.
- NP492919.RAF9GOPvS7QUsiYGo5k1Uoj5V7Kr_5uvpFUlnO2hAhxQ4130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492919.RAF9GOPvS7QUsiYGo5k1Uoj5V7Kr_5uvpFUlnO2hAhxQ4130_provenance.
- assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1404177.RAJRcmKoLXXsatOzPI92NQ_zlggIyZfbJiAkCe87MlXgI130_assertion description "[Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404177.RAJRcmKoLXXsatOzPI92NQ_zlggIyZfbJiAkCe87MlXgI130_provenance.